| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2015-12-21 |
| タイトル |
|
|
タイトル |
Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Bevacizumab |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Colorectal cancer |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
DPYD |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
ERCC1 |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
VEGFA |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Baba, Hideo
Baba, Yoshifumi
Uemoto, Shinji
Yoshida, Kazuhiro
Saiura, Akio
Watanabe, Masayuki
Maehara, Yoshihiko
Oki, Eiji
Ikeda, Yasuharu
Matsuda, Hiroyuki
Yamamoto, Masakazu
Shimada, Mitsuo
Taketomi, Akinobu
Unno, Michiaki
Sugihara, Kenichi
Ogata, Yutaka
Eguchi, Susumu
Kitano, Seigo
Shirouzu, Kazuo
Saiki, Yasumitsu
Takamori, Hiroshi
Mori, Masaki
Hirata, Toshihiko
Wakabayashi, Go
Kokudo, Norihiro
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Our previous study showed that administering oxaliplatin as first-line chemotherapy increased ERCC1 and DPD levels in liver colorectal cancers (CRCs) metastases. Second, whether the anti-VEGF monoclonal antibody bevacizumab alters tumoral VEGFA levels is unknown. We conducted this multicenter observational study to validate our previous findings on ERCC1 and DPD, and clarify the response of VEGFA expression to bavacizumab administration. 346 CRC patients with liver metastases were enrolled at 22 Japanese institutes. Resected liver metastases were available for 175 patients previously treated with oxaliplatin-based chemotherapy (chemotherapy group) and 171 receiving no previous chemotherapy (non-chemotherapy group). ERCC1, DPYD, and VEGFA mRNA levels were measured by real-time RT-PCR. ERCC1 mRNA expression was significantly higher in the chemotherapy group than in the non-chemotherapy group (P = 0.033), and were significantly correlated (Spearman's correlation coefficient = 0.42; P < 0.0001). VEGFA expression level was higher in patients receiving bevacizumab (n = 51) than in those who did not (n = 251) (P = 0.007). This study confirmed that first-line oxaliplatin-based chemotherapy increases ERCC1 and DPYD expression levels, potentially enhancing chemosensitivity to subsequent therapy. We also found that bevacizumab induces VEGFA expression in tumor cells, suggesting a biologic rationale for extending bevacizumab treatment beyond first progression. |
| 書誌情報 |
Oncotarget
巻 6,
号 32,
p. 34004-34013,
発行日 2015-08-19
|
| 出版者 |
|
|
出版者 |
Impact Journals LLC |
| EISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
19492553 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.18632/oncotarget.5227 |
| 権利 |
|
|
権利情報 |
c Impact Journals, LLC. |
| 権利 |
|
|
権利情報 |
This article is licensed under a Creative Commons Attribution 3.0 License. |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Oncotarget, 6(32), pp.34004-34013; 2015 |
Onco6_34004.pdf (2.7 MB)
